Y Intercept Hong Kong Ltd Has $307,000 Stock Holdings in Enhabit, Inc. (NYSE:EHAB)

Y Intercept Hong Kong Ltd reduced its position in Enhabit, Inc. (NYSE:EHAB) by 31.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 39,314 shares of the company’s stock after selling 17,700 shares during the period. Y Intercept Hong Kong Ltd owned about 0.08% of Enhabit worth $307,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of EHAB. FMR LLC increased its holdings in shares of Enhabit by 138.4% during the 3rd quarter. FMR LLC now owns 3,388 shares of the company’s stock worth $27,000 after acquiring an additional 1,967 shares during the last quarter. Gladius Capital Management LP increased its holdings in shares of Enhabit by 78.2% in the third quarter. Gladius Capital Management LP now owns 6,259 shares of the company’s stock valued at $49,000 after purchasing an additional 2,747 shares during the last quarter. Stoneridge Investment Partners LLC bought a new position in shares of Enhabit in the third quarter valued at about $81,000. Intech Investment Management LLC acquired a new stake in shares of Enhabit during the 3rd quarter worth about $96,000. Finally, Versor Investments LP bought a new stake in shares of Enhabit during the 3rd quarter worth about $97,000.

Enhabit Stock Up 0.7 %

Shares of NYSE EHAB opened at $8.49 on Wednesday. The stock has a 50-day moving average price of $8.14 and a two-hundred day moving average price of $7.90. Enhabit, Inc. has a 12 month low of $6.85 and a 12 month high of $11.74. The company has a current ratio of 1.46, a quick ratio of 1.46 and a debt-to-equity ratio of 0.85. The company has a market cap of $427.01 million, a price-to-earnings ratio of -3.66 and a beta of 1.83.

Insider Activity at Enhabit

In related news, Director Jeffrey Bolton purchased 4,000 shares of Enhabit stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $8.69 per share, for a total transaction of $34,760.00. Following the transaction, the director now owns 98,144 shares of the company’s stock, valued at approximately $852,871.36. This represents a 4.25 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Stuart M. Mcguigan acquired 15,000 shares of the stock in a transaction dated Tuesday, December 10th. The shares were bought at an average price of $8.81 per share, with a total value of $132,150.00. Following the completion of the transaction, the director now directly owns 46,810 shares of the company’s stock, valued at $412,396.10. The trade was a 47.15 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

EHAB has been the subject of a number of research analyst reports. Leerink Partners restated a “market perform” rating and set a $8.00 price objective (down previously from $8.50) on shares of Enhabit in a report on Tuesday, November 19th. Jefferies Financial Group upgraded Enhabit from a “hold” rating to a “buy” rating and boosted their price target for the company from $8.25 to $9.50 in a research note on Monday, December 9th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, Enhabit currently has a consensus rating of “Hold” and a consensus target price of $8.75.

Enhabit Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.